Teva Pharmaceutical Industries (TEVA) Cash from Investing Activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash from Investing Activities for 18 consecutive years, with -$491.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities fell 308.05% year-over-year to -$491.0 million; the trailing twelve-month figure through Jun 2026 stood at $38.0 million (down 95.81% YoY), and the FY2025 full-year result was $737.0 million, down 6.94% from the prior year.
• Cash from Investing Activities slipped to -$491.0 million in Q2 2026 per TEVA's latest filing, from $229.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $302.0 million in Q2 2023 and bottomed at -$491.0 million in Q2 2026.
• Historically, Cash from Investing Activities has averaged $160.6 million across 5 years, with a median of $180.0 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities jumped 79.17% in 2023, then tumbled 308.05% in 2026.
• Over 5 years, Cash from Investing Activities stood at $168.0 million in 2022, then surged by 79.17% to $301.0 million in 2023, then sank by 32.89% to $202.0 million in 2024, then dropped by 18.32% to $165.0 million in 2025, then tumbled by 397.58% to -$491.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$491.0 million, $229.0 million, and $165.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.